A multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis.

Abstract

Metoclopramide tablets were compared with placebo in the treatment of gastrointestinal symptoms in 40 patients with diabetic gastroparesis. Results of a 3-wk double-blind study indicate that metoclopramide at a dosage of one 10-mg tablet four times daily reduced nausea, vomiting, fullness, and early satiety and improved meal tolerance better than placebo. Statistically significant differences were noted for nausea and postprandial fullness. Mean gastric emptying assessed by radionuclide scintigraphy was significantly improved in the metoclopramide-treated group when compared with their baseline result. Metoclopramide is an effective agent for improving the upper gastrointestinal motor function in diabetic patients with gastroparesis.

• Authors: R W McCallum, D A Ricci, H Rakatansky, J Behar, J B Rhodes, G Salen, J Deren, A Ippoliti, H W Olsen, K Falchuk
• Journal: Diabetes care (Diabetes Care) 1983 Sep-Oct Vol. 6 Issue 5 Pg. 463-7 ISSN: 0149-5992 [Print] United States
• PMID: 6400707 (Publication Type: Clinical Trial, Journal Article, Multicenter Study)

Chemical References

• Metoclopramide

Topics

• Administration, Oral
• Adult
• Aged
• Clinical Trials as Topic
• Cranial Nerve Diseases (complications)
• Diabetic Neuropathies (complications)
• Double-Blind Method
• Female
• Humans
• Male
• Metoclopramide (administration & dosage, adverse effects, therapeutic use)
• Middle Aged
• Multicenter Studies as Topic
• Paralysis (drug therapy, etiology)
• Random Allocation
• Stomach Diseases (drug therapy, etiology)
• Vagus Nerve